Research Grade Anti-Human MET/c-Met/HGFR (REGN5093) (HY196106)

Даташит Поделиться продуктом Копировать информацию

Цена(USD): $

Спецификация:

100ug
1mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит

Обзор

Каталожный номер	HY196106
Описание	Anti-Human MET/c-Met/HGFR (REGN5093) (HY196106) is a research-grade recombinant antibody targeting Tyrosine-protein kinase Met. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Реактивность видов	Human
Применения	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Хозяинский вид	Human
Изотип	IgG
ID клона	REGN5093
Система экспрессии	Mammalian Cells
Клоональность	Monoclonal
Цель	Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET
Уровень эндотоксинов	Please contact the lab for this information.
Чистота	>95% purity as determined by SDS-PAGE.
Очистка	Protein A/G purified from cell culture supernatant.
Номер доступа	P08581
Форма	Liquid
Буфер хранения	0.01M PBS, pH 7.4. Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.
Устойчивость и хранение	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Альтернативные названия	REGN5093
Фон	Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant).
Примечание	For research use only. Not suitable for clinical or therapeutic use.

Изображения

SDS-PAGE

SDS-PAGE for Research Grade Anti-Human MET/c-Met/HGFR (REGN5093)
Bioactivity

Detects recombinant human MET/c-Met/HGFR (Catalog No: HY196021) in indirect ELISA